
The new dihydropyridine calcium antagonist isradipine versus nifedipine was tested in 41 patients with essential hypertension and cerebrovascular insufficiency. The tests have shown that isradipine shows all hemodynamic effects by significantly improving cerebral blood flow and it is better tolerated than nifedipine. It is concluded that isradipine is an effective agent in the long-term management of hypertensive patients at a high risk for cerebral hypoperfusion.
Adult, Male, Nifedipine, Hemodynamics, Drug Tolerance, Middle Aged, Cerebrovascular Disorders, Cerebrovascular Circulation, Chronic Disease, Hypertension, Drug Evaluation, Humans, Female, Isradipine, Aged
Adult, Male, Nifedipine, Hemodynamics, Drug Tolerance, Middle Aged, Cerebrovascular Disorders, Cerebrovascular Circulation, Chronic Disease, Hypertension, Drug Evaluation, Humans, Female, Isradipine, Aged
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
